CareDx (CDNA)
(Delayed Data from NSDQ)
$15.21 USD
-0.21 (-1.36%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $15.22 +0.01 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Brokerage Reports
CareDx, Inc. [CDNA]
Reports for Purchase
Showing records 61 - 80 ( 80 total )
Company: CareDx, Inc.
Industry: Medical Services
Company: CareDx, Inc.
Industry: Medical Services
1Q19 Financial Results Reported; Upgrade to Buy; Raise Price Target to $43
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
2018 Financial Results Reported; Reiterate Neutral and Raise Price Target to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
No Near-Term Kidney Transplant Testing Competitive Threat, in our View; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
Preliminary 2018 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
New AlloSure Clinical Utility Data Published; Financing Completed; Reiterate Neutral and Lower Price Target to $27
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
3Q18 Financial Results; 2018 Guidance Increased; Reiterate Neutral and Raise Price Target to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
Illumina-Partnered AlloSeq Suite Launching in 2019; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
HeartCare Registry Launched; Revenue Projections Increased; Reiterate Neutral and Raising Price Target to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
2Q18 Revenue up 48% YoY; Guidance Raised; Reiterate Neutral and Raising Price Target to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
Commercial Prospects of Competing Kidney Transplant Test Unclear; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
A Competing Post Kidney Transplant Test May Enter the Market in 2019; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
Physician Support for AlloSure; Downgrading to Neutral on Valuation; Raising Price Target to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
2018 1Q Results Reported; Reiterate Buy and Raising Price Target to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
AlloMap and AlloSure-Heart Combination Launched; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
Company: CareDx, Inc.
Industry: Medical Services
2017 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
Debt Refinanced With Perceptive Advisors; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
AlloSure to Drive Revenue Growth towards Profitability in 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: CareDx, Inc.
Industry: Medical Services
Revolutionizing Transplant Monitoring Non- Invasively; Initiating at Buy With $12 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R